Custom Recombinant Monoclonal Antibodies

摘要

Amsbio announce a new rabbit and mouse recombinant monoclonal antibody development service based upon a revolutionary technology platform.The DimAb~TM development platform is different from traditional hybridoma fusion technologies in that it can directly isolate IgG genes from B cells of immunised animals.Using this novel platform,a number of custom development projects have already been completed with high customer satisfaction.Comparing with other animals,rabbits have a unique B cell development process that is more distant from the human development process compared to rodents.Rabbit B cells utilise a dual affinity maturation mechanism combining gene conversion and somatic hypermutation.Additionally,rabbit IgG has a unique protein structure,including one subtype of IgG.These differences enable rabbits to produce antibodies with higher affinity and wider diversity.As a consequence,in recent years,rabbit monoclonal antibodies have gained popularity for a range of immunological assay developments,especially for pathology applications.On October 8th 2019,the first rabbit monoclonal antibody derived drug Beovu~R was approved by the FDA for the treatment of wet age-related macular degeneration（AMD).